Duraes AR, de Souza Roriz P, de Almeida Nunes B, et al. Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Manage- ment of Atrial Fibrillation Postoperatively: DAWA Pilot Study. Drugs R D. 2016;16:149 54. 21. Noseworthy PA, Yao X, Shah ND, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016;209:181 3. 22. Kim JY, Kim S-H, Myong J-P, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol. 2019;73:1123 31. 23. Dangas GD, Tijssen JGP, Wohrle J, et al. A controlled trial of rivaroxaban af- ter transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120 9. 2.5. Evaluation of Surgical and Interventional Risk 1. Edwards FH, Cohen DJ, O Brien SM, et al. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol. 2016;1:46 52. 2. Pilgrim T, Franzone A, Stortecky S, et al. Predicting mortality after trans- catheter aortic valve replacement: external validation of the Transcatheter Valve Therapy registry model. Circ Cardiovasc Interv. 2017;10:e005481. 3. Greason KL, Eleid MF, Nkomo VT, et al. Predictors of 1-year mortality after transcatheter aortic valve replacement. J Card Surg. 2018;33:243 9. 4. Arsalan M, Weferling M, Hecker F, et al. TAVI risk scoring using established versus new scoring systems: role of the new STS/ACC model. EuroInter- vention. 2018;13:1520 6. 5. Kiani S, Kamioka N, Black GB, et al. Development of a risk score to predict new pacemaker implantation after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:2133 42. 6. Thourani VH, O Brien SM, Kelly JJ, et al. 